The SWI/SNF chromatin-remodeling complex regulates gene expression and alters chromatin structures in an ATP-dependent manner. Recent sequencing efforts have shown mutations in BRG1 (SMARCA4), one of two mutually exclusive ATPase subunits in the complex, in a significant number of human lung tumor cell lines and primary non-small cell lung carcinoma (NSCLC) clinical specimens. To determine how BRG1 loss fuels tumor progression in NSCLC, molecular profiling was performed after restoration of BRG1 expression or treatment with an HDAC inhibitor or a DNMT inhibitor in a BRG1-deficient NSCLC cells. Importantly, validation studies from multiple cell lines revealed that BRG1 re-expression led to substantial changes in the expression of CDH1, CDH3, EHF and RRAD that commonly undergo silencing by other epigenetic mechanisms during NSCLC development. Furthermore, treatment with DNMT inhibitors did not restore expression of these transcripts indicating that this common mechanism of gene silencing did not account for their loss of expression. Collectively, BRG1 loss is an important mechanism for the epigenetic silencing of target genes during NSCLC development.
Introduction
Lung and bronchus carcinoma remain two of the most lethal cancers in the United States with over 90% of affected individuals succumbing to this disease. Over 85% of these cancers will be classified as non-small cell lung carcinoma (NSCLC) making them the primary clinical focus.
For many cancers, treatments for early stage tumors have proven effective while metastatic disease often carries a very poor prognosis (most patients with metastatic lung carcinoma show an overall survival rate of <5% at 5 years). During the last 25 years, investigators have identified many of the genetic changes underlying the appearance of NSCLC including
mutations of BRAF, KRAS, EGFR, FHIT, HER2/NEU, RB, p16
We have previously shown that re-expression of BRG1 in human cell lines lacking expression of both mutually exclusive ATPases, BRG1 and BRM/SMARCA2, induces expression of genes often associated with epigenetic silencing (17) (18) (19) (20) . We also observed some overlap between genes activated by BRG1 expression and those activated by treatment with the DNA methyltransferase (DNMT) inhibitor 5dAzaC (17) . However, we did not assess the effects of histone acetylation in this study, another mechanism for gene silencing (21). Because we only examined a limited number of genes, we could not determine how commonly genes activated by BRG1 expression overlapped with those induced by DNMT inhibition or by HDAC inhibition.
To address the question of how BRG1 inactivation contributes to NSCLC development, we carried out a gene expression array analysis on a BRG1/BRM-deficient cell line treated with a DNMT inhibitor, a HDAC inhibitor or infected with an adenovirus expressing BRG1. An analysis of the results showed that BRG1 re-expression activated a greater number of genes than either chemical reagent. Furthermore, the number of genes activated by both BRG1 and HDAC inhibition was greater than the number induced by both BRG1 and DNMT inhibition. We also did not observe global changes in DNA methylation patterns after BRG1 re-expression.
Therefore, it appears that BRG1 loss contributes to gene silencing during NSCLC development via a mechanism independent of changes in DNA methylation. We also identified several important cancer-associated genes that may represent key downstream targets for SWI/SNF complex activity. These findings provide further insight into the role of aberrant SWI/SNF complex activity during NSCLC progression as well as opening new avenues for treatment of the patients.
Material and Methods

Cell culture
The human NSCLC cell lines H460, H522 and A427 and the human adrenal carcinoma cell line SWI3 were obtained from the ATCC and were grown in RPMI1640 with 10% FBS (Gibco, Life Technologies). All experiments were performed with cell lines within 20 passages of receipt (<3 months) to ensure the identity of each cell line. For BRG1 re-expression, we used an adenovirus expressing BRG1 and GFP, kindly provided by Dr. Bremner, Toronto Western
Research Institute (22, 23). As a control we used an adenovirus expressing GFP alone provided by the UNC Vector Core Facility, (24). Adenovirus infection followed our previously published protocol (24).
Microarray analyses
Total RNA was extracted from H522 cells either untreated or treated with vehicle, dimethyl sulfoxide (DMSO), 5µM 5-aza-2'-deoxycytidine (5dAzaC), 100nM Trichostatin A (TSA) or infected with adenovirus expressing GFP-tagged BRG1 or GFP alone for 48 hours. RNA was labeled with Cy3 (treated or infected) and Cy5 (untreated) and hybridized to 4X44 whole human genome microarrays (cat#G4112F, Agilent Technologies, Wilmington, Delaware, USA) by the UNC Lineberger Genomics Core for Agilent microarray analysis. After acquiring the raw images from the Agilent Microarray Scanner with SureScan Technology (Agilent Technologies), the raw data from captured image files was extracted using Agilent Extraction Software (Agilent Technologies) and uploaded into UNC Microarray Database (UMD). The normexp background correction and loess normalization procedures were applied to the probe-level data (25).
Expression measurements for each gene were calculated by computing the mean of the normalized intensity values for all probes mapping to that gene, as specified in a gene annotation database. This produced expression values for 19,749 genes. These data are available at GEO (http://www.ncbi.nlm.nih.gov/geo/), under accession number GSE54033.
The SAMR package was used to detect differentially expressed genes by comparing the expression values in the 5dAzaC-treated and TSA-treated cells to the expression values in the DMSO treated cells, while Ad-BRG1-GFP infected cells were compared to Ad-GFP infected cells in an effort to isolate the effect of BRG1 re-expression. (26). Gene expression values were first standardized within each array. For each of the above comparisons, we then identified differentially expressed genes using a median FDR threshold of .001. R 2.15.1 (27) was used to perform statistical analyses as well as create gene expression heatmaps and Venn diagrams using the gplots and VennDiagram packages, respectively (28, 29).
Gene transfection
For validation studies, we carried out transient transfections using either Fugene 6 (Promega) or Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Either the pBJ5-BRG1 plasmid expressing BRG1 or the empty vector pcDNA was transfected to each plate, and the cells were harvested for both RNA and protein 48 hours post-transfection as previously described (30) .
Immunoblotting
Immunoblotting was performed as previously described (31) . Protein lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF. The membrane was incubated in blocking buffer and then with a primary antibody overnight at 4°C. After washing, the membrane was incubated with an HRP-conjugated secondary antibody in blocking buffer. The primary antibodies included: BRG1 (A300-813A, 
Quantitative RT-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen) according to manufacturer's protocol, and was quantified by nanodrop spectrophotometry. 1 μg was used for cDNA synthesis and reverse transcription was performed using M-MLV reverse transcriptase (Invitrogen) with random primers (Invitrogen) and dNTP mix according to manufacturer's instructions. We determined the amount of cDNA using ABI 7900HT sequence detection system (Applied Biosystems) with TaqMan Universal PCR Master Mix reagents and relative quantification was analyzed by the 2−ΔΔCt method with β-actin as an endogenous control. The primers used to detect the expression of CDH1 (Hs00170423_m1), CDH3 (Hs00354998_m1), RRAD (Hs00188163_m1), EHF (Hs00171917_m1), CD44 (Hs01075861_m1), SMARCA4 (Hs00946396_m1) and β-ACTIN (Hs01060665_g1) were purchased from Life Technologies.
Restriction Genomic Landscape Scanning (RGLS)
We used the RLGS technique as previously described (32, 33) . Briefly, 48 hours after transfection with empty vector or pBJ5-BRG1 into H522 or A427, cells were harvested for high molecular weight genomic DNA using Proteinase K digestion followed by phenol chloroform extraction and ethanol precipitation as previously described (34) . DNA was digested with NotI and EcoRV for first dimension separation followed by in-gel HinfI digestion prior to second dimension separation, and ~2000 sites visually compared. Differential methylation was detected by either the absence or decrease in signal intensity (>50%). Each gel is internally controlled for successful restriction digests. In an incomplete digest, the strong RLGS spots with BRG1 re-expression or 100nM TSA as previously reported (18, (37) (38) (39) (40) (41) (42) (43) . All cells were treated or infected for 48 hours. After hybridization to Agilent whole human genome microarrays, the data was processed as described in the Material and Methods. Expression data for a total of 19,749 genes was available for analysis.
We first analyzed these data by hierarchically clustering both the genes and the arrays in the expression data and then creating a heat map to look for common patterns of gene expression.
As shown in Figure 2 , the 4 replicates from each treatment group clustered together, which shows consistency of gene expression patterns among the replicates. Of interest, the groups infected with adenovirus showed greater similarity to each other than to either TSA or 5-dAzaC treatments. It also appeared that infection with Ad-GFP alone caused unique changes in gene expression compared to the other treatment groups. Furthermore, the DMSO treatment control showed the least similarity to any of the other treatment groups while TSA and 5-dAzaC treatments showed the most similarity. Therefore, for gene expression altered by TSA or 5-dAzaC treatments, we searched for differential expression between each treatment group and the DMSO treated cells. We identified genes whose expression was induced by BRG1 reexpression by comparing the Ad-BRG1-GFP infection to the Ad-GFP infection.
We first looked for genes that showed changed expression after Ad-BRG1 infection. Our results found expression levels for 5527 genes increased and 6510 decreased after BRG1-GFP reexpression normalized to GFP expression alone (Supplemental Table 1 ). However, this number represents an over estimation because some genes showed decreased expression under all treatment conditions (Supplemental Table 1 ). In a similar vein, expression of 2436 genes increased and 2763 genes decreased after 5-dAzaC treatment (Supplemental Table 2 ). In contrast, we observed fewer changes in gene expression after TSA treatment, where 560 genes went up and 995 genes went down (Supplemental Table 3 ). We also identified genes whose expression increased after 2 different treatments. We observed 429 genes that showed increased expression after either 5-dAzaC treatment or BRG1 reexpression (Supplemental Table 4 ). However, to be conservative in these analyses, we first focused only on those genes whose expression increased >2 fold compared to the parental cell line. Of these 429 genes, Table 1 lists the 145 genes that increased more than 2 fold after BRG1 re-expression including genes such as CDH3 and GDF15 that are associated with human tumor development (44, 45) . Interestingly, GDF15 was previously reported to undergo silencing by histone acetylation (46) . In a similar analysis for genes whose expression increased after TSA treatment or BRG1 re-expression, we found 186 genes (Supplemental Table 5 ). Of 140 genes from this group that went up by more than 2-fold after BRG1 reexpression, CDH1 showed the most robust increase in expression while CD44, KRT4, KRT8
and KRT18 also showed strong induction (Table 2 ). Finally, we looked for genes whose expression went up under all three conditions. This group contained the fewest genes (86), of which 55 genes increased by more than 2 fold after BRG1 re-expression (Table 3,   Supplemental Table 6 ). Interestingly, GADD45A, a stress responsive gene, showed strong induction under all 3 conditions (Supplemental Table 6 ) (47). Finally, we identified genes that showed increased expression after TSA or 5-dAzaC treatment but not BRG1 (Supplemental Table 7 ). We found 170 genes, of which 148 increased by at least 2-fold after TSA treatment.
These results are summarized in a Venn diagram in Figure 2B .
Validation of gene expression array data.
One caveat from studies using adenovirus infection to express proteins is the significant production of protein by the adenovirus infection. To address this issue, we re-expressed BRG1 in the H522 cell line by gene transfection to minimize overexpression. We also included a showed that RRAD, a member of the RAS superfamily, is epigenetically silenced by DNA methylation in a large percentage of NSCLC while EHF, a member of the ETS transcription factor family, is silenced in prostate cancer (48, 49) . CDH3 (P-cadherin) maps next to CDH1 and can also undergo silencing during human tumor development (45) .
As shown in Figure 1B , we observed increased expression of these genes in H522 consistent with microarray data. However, we found increases only in CD44, EHF and RRAD expression after BRG1 re-expression in the A427 cell line, indicating differences between these 2 NSCLC cell lines. We also assessed protein expression by Western blot analysis for genes with available antibodies ( Figure 1C) . The Western blot data in Figure 1C 
successfully used to detect changes in DNA methylation in primary NSCLC samples (50) . We first demonstrated that our treatment conditions with 5-dAzaC led to re-expression of methylation-silenced CDH1 in the H460 NSCLC cell line as previously reported ( Figure 3A ) (51) .
In contrast, only treatment with TSA +/-5-dAzaC or infection with Ad-BRG1 led to CDH1 and CD44 expression in H522 cells, in agreement with the gene expression array results ( Figure 3A ).
RLGS analysis of H522 cells transfected with vector or BRG1 revealed only three prominent landmarks that appeared after BRG1 re-expression ( Figure 3B ). However, sequencing of these DNAs revealed that they originated from the BRG1 transgene and not from changes in methylation of the H522 cellular DNA. Similar results were observed for the A427 cell line (Supplementary Figure 1) . We could not detect any additional changes after BRG1 reexpression. Therefore, this "snapshot" of global DNA methylation did not show major changes after BRG1 re-expression. We cannot, off course, exclude that DNA methylation changes below the detection limit of about 5% change occurred.
Finally, we examined whether the DNA methylation status of these genes would predict their response to BRG1 re-expression i.e. do high levels of DNA methylation inhibit the effects of BRG1 re-expression? To address this issue, we took advantage of a recent study that used DNA methylation arrays to compare the patterns among 69 human NSCLC cell lines including H522 and A427 (35) . We compared the methylation patterns on 4 genes that showed increased expression in one or both cell lines, CD44, CDH1, RRAD and CDH3. As shown in of BRG1 that appear to be degraded (11, 18) . However, in these cohorts, five of eight mutations in squamous cell and ten out of twenty mutations in adenocarcinomas are missense.
Therefore, determining the effects of these single amino acids changes on protein function becomes imperative. Importantly, several recent reports have shown that missense mutations in BRG1 can dramatically alter its biological activity (30, 66) . Whether these BRG1 mutant proteins can also result in gene silencing remains an important unanswered question. Table Legends   Table 1 . Genes up-regulated by both 5-dAzaC treatment and BRG1 re-expression.
Differentially expressed genes were identified, as described in Material and Methods. Of the 429 genes up-regulated in both 5-dAzaC treatment vs. DMSO and BRG1-GFP re-expression vs.
GFP, the 145 genes that increased more than two fold after BRG1 re-expression are shown. Table 2 .
Genes up-regulated by both TSA treatment and BRG1 re-expression.
Differentially expressed genes were identified, as described in Material and Methods. Of the 186 genes up-regulated in both TSA treatment vs. DMSO and BRG1-GFP re-expression vs.
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